EU OKs Continued Use Of Etifoxine For Anxiety Despite Toxicity Concerns
Executive Summary
The European Medicines Agency has also recommended that EU member states go ahead and approve Tiofarma’s midazolam nasal spray Nasolam for convulsive seizures, while a review of a lidocaine/prilocaine product from French firm International Drug Development has been stopped after the applicant withdrew its decentralized marketing authorization application.
You may also be interested in...
EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season
The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination.
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.
New Swiss Database To Cut Costs Of GMP/GDP Certification
A new database being set up in Switzerland is expected to improve the exchange of GMP and GDP information between the regulatory authorities and pharmaceutical companies and offer free access to electronic certificates.